X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (793) 793
life sciences & biomedicine (786) 786
humans (700) 700
cardiovascular system & cardiology (638) 638
cardiac & cardiovascular systems (596) 596
female (560) 560
male (558) 558
middle aged (501) 501
aged (492) 492
abridged index medicus (376) 376
risk factors (317) 317
treatment outcome (257) 257
heart attacks (209) 209
mortality (191) 191
cardiovascular (189) 189
myocardial infarction (186) 186
prospective studies (161) 161
time factors (159) 159
acute coronary syndromes (154) 154
registries (149) 149
care and treatment (146) 146
cardiovascular disease (143) 143
follow-up studies (142) 142
stroke (133) 133
coronary heart disease (129) 129
peripheral vascular disease (124) 124
percutaneous coronary intervention (121) 121
cardiac patients (119) 119
platelet aggregation inhibitors - therapeutic use (119) 119
heart attack (118) 118
cardiovascular diseases (114) 114
general & internal medicine (111) 111
myocardial infarction - mortality (110) 110
myocardial infarction - therapy (110) 110
medicin och hälsovetenskap (109) 109
medical and health sciences (108) 108
risk assessment (107) 107
prognosis (104) 104
cardiology and cardiovascular medicine (103) 103
medicine, general & internal (102) 102
drug therapy (101) 101
cardiology (100) 100
electrocardiography (100) 100
patient outcomes (100) 100
coronary vessels (99) 99
double-blind method (98) 98
stents (98) 98
aged, 80 and over (96) 96
drug therapy, combination (95) 95
hemorrhage - chemically induced (94) 94
thrombosis (94) 94
aspirin (93) 93
kardiologi (92) 92
ticlopidine - analogs & derivatives (90) 90
cardiac and cardiovascular systems (89) 89
internal medicine (89) 89
platelet aggregation inhibitors - administration & dosage (88) 88
diabetes (87) 87
acute coronary syndrome (84) 84
clinical medicine (84) 84
patients (83) 83
clopidogrel (81) 81
coronary artery disease (81) 81
ischemia (81) 81
klinisk medicin (80) 80
bleeding (79) 79
adult (78) 78
platelet aggregation inhibitors - adverse effects (78) 78
clinical trials (77) 77
research (76) 76
transluminal angioplasty (75) 75
ticagrelor (73) 73
angioplasty (71) 71
analysis (70) 70
kaplan-meier estimate (69) 69
coronary angiography (66) 66
acute coronary syndrome - drug therapy (63) 63
angioplasty, balloon, coronary (61) 61
heart failure (61) 61
usage (61) 61
myocardial infarction - drug therapy (60) 60
adenosine - analogs & derivatives (59) 59
studies (59) 59
anticoagulants (58) 58
myocardial infarction - diagnosis (58) 58
health aspects (57) 57
incidence (57) 57
myocardial infarction - etiology (57) 57
myocardial infarction - epidemiology (56) 56
recurrence (56) 56
clinical outcomes (51) 51
medical research (51) 51
proportional hazards models (51) 51
acute coronary syndrome - mortality (50) 50
dosage and administration (50) 50
hemorrhage (50) 50
medical colleges (49) 49
atherosclerosis (48) 48
atrial fibrillation (48) 48
health risk assessment (48) 48
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1255) 1255
French (10) 10
Spanish (5) 5
Polish (4) 4
Italian (2) 2
Portuguese (2) 2
German (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2017, Volume 377, Issue 16, pp. 1513 - 1524
In this trial, dabigatran plus a P2Y 12 inhibitor was compared with warfarin plus a P2Y 12 inhibitor and aspirin after PCI in patients with atrial... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2010, Volume 376, Issue 9749, pp. 1320 - 1328
Summary Background In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute coronary syndromes, ticagrelor reduced the composite outcome of... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Ticlopidine - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Male | Adenosine - adverse effects | Adenosine - therapeutic use | Ticlopidine - adverse effects | Female | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Pharmacogenetics | Genotype | Ticlopidine - analogs & derivatives | Randomized Controlled Trials as Topic | Acute Coronary Syndrome - drug therapy | Phenotype | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Cytochrome P-450 CYP2C19 | Adenosine - analogs & derivatives | ATP Binding Cassette Transporter, Sub-Family B | Aged | Polymorphism, Single Nucleotide | Acute Coronary Syndrome - genetics | Care and treatment | Patient outcomes | Physiological aspects | Clopidogrel | Dosage and administration | Single nucleotide polymorphisms | Health aspects | Coronary heart disease | Studies | Heart attacks | Statistical analysis | Metabolites | Genetics | Drug therapy | Gene expression | Acute coronary syndromes | Myocardial infarction | Stroke | Single-nucleotide polymorphism | Arteries | Bleeding | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 12/2014, Volume 371, Issue 23, pp. 2155 - 2166
Patients who had received a drug-eluting stent and then dual antiplatelet therapy for 12 months were randomly assigned to 18 more months of therapy or aspirin... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Piperazines - administration & dosage | Prasugrel Hydrochloride | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Aspirin - administration & dosage | Incidence | Time Factors | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Myocardial Ischemia - mortality | Thrombosis - prevention & control | Drug Therapy, Combination | Myocardial Ischemia - epidemiology | Platelet Aggregation Inhibitors - adverse effects | Drug-Eluting Stents | Drug Administration Schedule | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Myocardial Ischemia - therapy | Aged | Hemorrhage - chemically induced | Aggregation | Treatment outcome | Care and treatment | Usage | Blood platelets | Analysis | Drug-eluting stents | Dosage and administration | Cardiovascular diseases | Thrombosis | Health aspects | Blood clot | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Drug delivery | Patients | Bleeding | Clinical outcomes | Cerebrovascular system | Coronary vessels | Implants | Clopidogrel | Drug therapy | Stents | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
by Thygesen, Kristian and Alpert, Joseph S and Jaffe, Allan S and Simoons, Maarten L and Chaitman, Bernard R and White, Harvey D and Katus, Hugo A and Apple, Fred S and Lindahl, Bertil and Morrow, David A and Clemmensen, Peter M and Johanson, Per and Hod, Hanoch and Underwood, Richard and Bax, Jeroen J and Bonow, Robert O and Pinto, Fausto and Gibbons, Raymond J and Fox, Keith A and Atar, Dan and Newby, L. Kristin and Galvani, Marcello and Hamm, Christian W and Uretsky, Barry F and Gabriel Steg, Ph and Wijns, William and Bassand, Jean-Pierre and Menasché, Phillippe and Ravkilde, Jan and Ohman, E. Magnus and Antman, Elliott M and Wallentin, Lars C and Armstrong, Paul W and Januzzi, James L and Nieminen, Markku S and Gheorghiade, Mihai and Filippatos, Gerasimos and Luepker, Russell V and Fortmann, Stephen P and Rosamond, Wayne D and Levy, Dan and Wood, David and Smith, Sidney C and Hu, Dayi and Lopez-Sendon, José-Luis and Robertson, Rose Marie and Weaver, Douglas and Tendera, Michal and Bove, Alfred A and Parkhomenko, Alexander N and Vasilieva, Elena J and Mendis, Shanti and Baumgartner, Helmut and Ceconi, Claudio and Dean, Veronica and Deaton, Christi and Fagard, Robert and Funck-Brentano, Christian and Hasdai, David and Hoes, Arno and Kirchhof, Paulus and Knuuti, Juhani and Kolh, Philippe and McDonagh, Theresa and Moulin, Cyril and Popescu, Bogdan A and Reiner, Željko and Sechtem, Udo and Sirnes, Per Anton and Torbicki, Adam and Vahanian, Alec and Windecker, Stephan and Morais, Joao and Aguiar, Carlos and Almahmeed, Wael and Arnar, David O and Barili, Fabio and Bloch, Kenneth D and Bolger, Ann F and Bøtker, Hans Erik and Bozkurt, Biykem and Bugiardini, Raffaele and Cannon, Christopher and de Lemos, James and Eberli, Franz R and Escobar, Edgardo and Hlatky, Mark and James, Stefan and Kern, Karl B and Moliterno, David J and Mueller, Christian and Neskovic, Aleksandar N and Pieske, Burkert Mathias and Schulman, Steven P and Storey, Robert F and Taubert, Kathryn A and Vranckx, Pascal and Wagner, Daniel R and Classification Subcommittee and Heart Failure Subcommittee and Authors/Task Force Members Chairpersons and ECG Subcommittee and Imaging Subcommittee and Trials & Registries Subcommittee and Biomarker Subcommittee and Intervention Subcommittee and Global Perspective Subcommittee and ESC Committee for Practice Guidelines (CPG) and the Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction and Epidemiology Subcommittee and Document Reviewers and Joint ESC ACCF AHA WHF Task Force and Writing Group on the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction
European heart journal, ISSN 1522-9645, 10/2012, Volume 33, Issue 20, pp. 2551 - 2567
Journal Article